Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Interventional Radiology · Renal Angiomyolipoma

Treatment Options: Procedures and Medications

At a Glance

Renal angiomyolipoma treatment is tailored to symptoms, tumor growth, bleeding risk, location, and whether tuberous sclerosis complex is present. Embolization or partial nephrectomy can treat an individual tumor, while everolimus may shrink multiple growing tumors in eligible people with TSC.

Deciding when and how to treat a renal angiomyolipoma (AML) is a personalized process. While many AMLs are safely managed with active surveillance, certain “triggers”—such as persistent pain, rapid growth, or a high risk of bleeding—may lead you and your doctor to discuss active treatment [1][2].

Today, the goal of treatment is to protect your health while preserving as much of your healthy kidney tissue as possible, a concept known as nephron-sparing care [3][4].

Selective Arterial Embolization (SAE)

Selective Arterial Embolization (SAE) is a minimally invasive procedure performed by an interventional radiologist. A small tube (catheter) is inserted into a blood vessel in your groin or wrist and guided to the specific artery feeding the tumor. Materials are released to block that artery, “starving” the tumor of its blood supply [5][6].

  • The Benefits: It is highly effective for stopping active bleeding during an emergency and is less invasive than surgery, typically requiring a shorter hospital stay [7][8].
  • The Drawbacks: Because the tumor tissue remains in your body, it may not shrink completely. Depending on the center and the tumor, some patients eventually need a repeat procedure if the tumor revascularizes (regains blood flow) [9]. Risks include non-target embolization (blocking healthy vessels) and access-site problems.
  • Post-Embolization Syndrome (PES): A significant number of patients experience PES, which includes temporary fever, flank pain, nausea, or vomiting as the tissue reacts to the loss of blood flow [9]. This is usually managed with rest and medication and typically resolves within a few days [10].

Contact your care team promptly if you experience worsening pain, persistent vomiting, high fever, faintness, or reduced urine output after an embolization.

Partial Nephrectomy

A partial nephrectomy is a surgery to remove the tumor while leaving the rest of the healthy kidney intact. This is often done using a robotic-assisted approach, which allows for high precision [11][3].

  • The Benefits: This is a direct physical removal of the mass. It also allows a pathologist to examine the entire tissue, which is vital if there was diagnostic uncertainty (e.g., if it was a fat-poor tumor that resembled cancer) [6][4].
  • The Drawbacks: As a major surgery, it carries risks of bleeding, urine leaks, infection, and a longer recovery time [7]. While it offers excellent long-term control of that specific mass, patients with TSC can still form new tumors elsewhere in the kidney.

Medication for TSC-Associated AML

For patients with Tuberous Sclerosis Complex (TSC), the approach often shifts from procedures to medication. Because TSC causes multiple tumors in both kidneys, repeated surgeries or embolizations could eventually damage too much kidney tissue [12].

mTOR Inhibitors (Everolimus): These are daily pills that target the specific genetic pathway responsible for tumor growth in TSC.

  • When it is used: International guidelines recommend an mTOR inhibitor for TSC patients who can tolerate systemic therapy and who have asymptomatic, growing tumors larger than 3 cm [12][13].
  • Effectiveness: Clinical trials show that a majority of patients see their kidney tumors shrink significantly, providing excellent long-term control as long as they remain on the drug [14].
  • Important Risks & Side Effects: Though it involves no incisions, everolimus is a powerful systemic therapy. Side effects include stomatitis (mouth sores), increased infection risk, fatigue, elevated cholesterol and blood sugar, noninfectious pneumonitis (lung inflammation), and potential wound-healing issues [14]. It requires routine laboratory monitoring, and female patients require pregnancy planning/contraception counseling. If the medication is stopped, the tumors will likely begin to grow again [15][16].
Feature Embolization (SAE) Partial Nephrectomy mTOR Inhibitors (TSC only)
Approach Catheter (Minimally Invasive) Surgical Removal Systemic Therapy (Daily Pill)
Primary Goal Shrink tumor/Stop acute bleed Remove the specific tumor Control/Shrink multiple tumors
Tissue Diagnosis? No Yes No
Major Risks Post-embolization syndrome, re-treatment Bleeding, urine leak, longer recovery Infections, metabolic changes, mouth sores

Common questions in this guide

When should an angiomyolipoma be treated instead of monitored?
Many renal angiomyolipomas can be monitored with regular follow-up. Active treatment may be considered when the tumor causes persistent pain, grows quickly, or has a high risk of bleeding; the choice also depends on its size, location, and your overall health.
How does embolization treat a renal angiomyolipoma?
During selective arterial embolization, a radiologist guides a thin tube through a blood vessel in the groin or wrist to the artery feeding the tumor. Material is released to block blood flow, which can stop active bleeding and reduce the tumor’s blood supply, but the tumor tissue remains and a repeat procedure may sometimes be needed.
What should I expect after angiomyolipoma embolization?
Temporary fever, flank pain, nausea, or vomiting can occur as post-embolization syndrome and usually improve within a few days with rest and medicine. Call your care team promptly for worsening pain, persistent vomiting, high fever, faintness, or reduced urine output.
What is the difference between partial nephrectomy and embolization for AML?
Partial nephrectomy surgically removes the tumor while leaving healthy kidney tissue and provides a full tissue sample for examination. Embolization is less invasive and can control bleeding, but it leaves the tumor in place and may require repeat treatment; surgery has risks such as bleeding, urine leaks, infection, and longer recovery.
When is everolimus used for TSC-associated angiomyolipoma?
For people with tuberous sclerosis complex, everolimus may be recommended when tumors are asymptomatic, growing, and larger than 3 cm, if the person can safely take systemic treatment. It can shrink multiple kidney tumors, but it requires regular laboratory monitoring and may cause mouth sores, infections, fatigue, blood sugar or cholesterol changes, lung inflammation, and wound-healing problems. Tumors may begin growing again if the medicine is stopped.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on angiomyolipoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my tumor's location and size, would you recommend selective arterial embolization (SAE) or a robotic partial nephrectomy if we decide to treat it?
  2. 2.What is the risk of my tumor needing a second procedure if we choose embolization versus surgery?
  3. 3.If I have TSC-associated AML, am I a candidate for an mTOR inhibitor like everolimus to shrink the tumor instead of having a procedure?
  4. 4.How do you manage post-embolization syndrome if I develop pain or fever after the procedure?
  5. 5.How much healthy kidney tissue do you expect to preserve with each of the treatment options we are considering?

References

References (16)
  1. 1

    New Trends and Evidence for the Management of Renal Angiomyolipoma: A Comprehensive Narrative Review of the Literature.

    Restrepo JCÁ, Millan DAC, Sabogal CAR, et al.

    Journal of kidney cancer and VHL 2022; (9(1)):33-41 doi:10.15586/jkcvhl.v9i1.177.

    PMID: 35096516
  2. 2

    Evolving horizons in renal angiomyolipoma: two decades of management strategies and clinical perspectives in a single institutional study.

    Keles A, Iplikci A, Arikan O, et al.

    The aging male : the official journal of the International Society for the Study of the Aging Male 2024; (27(1)):2346308 doi:10.1080/13685538.2024.2346308.

    PMID: 38709235
  3. 3

    Are nephrometry scores accurate for the prediction of outcomes in patients with renal angiomyolipoma treated with robot-assisted partial nephrectomy? A multi-institutional analysis.

    Uleri A, Diana P, Lughezzani G, et al.

    Minerva urology and nephrology 2022; (74(6)):730-737 doi:10.23736/S2724-6051.22.04848-0.

    PMID: 35622350
  4. 4

    Evidence-based protocol-led management of renal angiomyolipoma: A review of literature.

    Vaggers S, Rice P, Somani BK, et al.

    Turkish journal of urology 2021; (47(Supp. 1)):S9-S18 doi:10.5152/tud.2020.20343.

    PMID: 32966208
  5. 5

    Urgent transcatheter arterial embolization for the treatment of ruptured renal angiomyolipoma with spontaneous hemorrhage.

    Duan XH, Zhang MF, Ren JZ, et al.

    Acta radiologica (Stockholm, Sweden : 1987) 2016; (57(11)):1360-1365 doi:10.1177/0284185115588125.

    PMID: 26133195
  6. 6

    Giant renal pseudoaneurysm complicating angiomyolipoma in a patient with tuberous sclerosis complex: An unusual case report and review of the literature.

    Esmat HA, Naseri MW

    Annals of medicine and surgery (2012) 2021; (62()):131-134 doi:10.1016/j.amsu.2021.01.014.

    PMID: 33520209
  7. 7

    Arterial Embolization versus Robotic Partial Nephrectomy for the Treatment of Renal Angiomyolipomas.

    Ouzaid I, Gabriel PE, Lee B, et al.

    International braz j urol : official journal of the Brazilian Society of Urology 2025; (51(5)).

    PMID: 40513023
  8. 8

    Comparison of Superselective Renal Artery Embolization versus Retroperitoneal Laparoscopic Partial Nephrectomy in Ruptured Hemorrhagic Renal Angiomyolipoma: A Single-Center Study.

    Li Z, Yang L, Yang H, et al.

    Diseases (Basel, Switzerland) 2024; (12(9)) doi:10.3390/diseases12090218.

    PMID: 39329887
  9. 9

    Transarterial Embolization of Angiomyolipoma: A Systematic Review.

    Murray TE, Doyle F, Lee M

    The Journal of urology 2015; (194(3)):635-9.

    PMID: 25916674
  10. 10

    Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study.

    Tsuchiya S, Saiga A, Yokota H, et al.

    Interventional radiology (Higashimatsuyama-shi (Japan) 2023; (8(1)):1-6 doi:10.22575/interventionalradiology.2021-0015.

    PMID: 36936258
  11. 11

    Robotic Partial Nephrectomy in the Treatment of Renal Angiomyolipoma.

    Kara O, Akca O, Zargar H, et al.

    Journal of endourology 2016; (30(3)):275-9 doi:10.1089/end.2015.0624.

    PMID: 26654096
  12. 12

    Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.

    Kingswood JC, Bissler JJ, Budde K, et al.

    Nephron 2016; (134(2)):51-58 doi:10.1159/000448293.

    PMID: 27504842
  13. 13

    Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.

    Samuels JA

    Clinical journal of the American Society of Nephrology : CJASN 2017; (12(7)):1196-1202 doi:10.2215/CJN.08150816.

    PMID: 28302901
  14. 14

    Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.

    Bissler JJ, Kingswood JC, Radzikowska E, et al.

    PloS one 2017; (12(8)):e0180939 doi:10.1371/journal.pone.0180939.

    PMID: 28792952
  15. 15

    Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.

    Bissler JJ, Nonomura N, Budde K, et al.

    PloS one 2018; (13(9)):e0201005 doi:10.1371/journal.pone.0201005.

    PMID: 30192751
  16. 16

    Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex.

    Hatano T, Inaba H, Endo K, Egawa S

    International journal of urology : official journal of the Japanese Urological Association 2017; (24(11)):780-785 doi:10.1111/iju.13428.

    PMID: 28905429

This page explains renal angiomyolipoma treatment options for education only and does not replace medical advice. Your urologist, interventional radiologist, and TSC care team can help weigh kidney preservation, bleeding risk, side effects, and recovery in your situation.